



Curriculum Vitae

Piera Federico, MD

Personal Information

Name: Piera FEDERICO

Date of birth: 31 May 1980 **Place:** Piedimonte Matese (CE)

Nationality: Italian

Gender: Female

Professional address:

U.O. Oncologia Medica - A. O. "G.Rummo"
Via dell'Angelo, n.1 - 82100 Benevento

Present Position:

Oncologist at the Oncology Division- A.O. "G.Rummo"-Benevento

Physician experienced in urological tumors.

Medical Licence: Mar 2007 no. 002737 (Benevento)

Professional experience:

2012-2014: Ph.D, Postgraduate physician at the Oncology Molecular and Clinical Endocrinology Division (International doctorate programme in Oncology Molecular and Clinical Endocrinology Division) - Università degli Studi "Federico II" of Naples
2007-2011: Oncology specialising physician at the Oncology Molecular and Clinical Endocrinology Division - Università degli Studi "Federico II" of Naples
2003-2006- Internal University physician at the Pathological Anatomy Division of Università Cattolica Sacro Cuore "Gemelli" - Rome

Academic studies;

Medical Education:

2012-2014: Postgraduate physician at the Oncology Molecular and Clinical Endocrinology Division, Università degli Studi "Federico II" of Naples.
2008-2011: attending Specialty in Oncology of University "Federico II" of Naples
2001-2006: Medical Degree of Final degree mark: 110/110 cum laude of University "Cattolica" of Rome.

Publications: on international reviews

key publications:

Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review.

Di Lorenzo G, **Federico P**, De Placido S, Buonerba C.

Crit Rev Oncol Hematol. 2015 Dec;96(3):534-41.doi:10.1016/j.critrevonc.2015.07.004.Epub.

Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger.

Caffo O, Ortega C, Di Lorenzo G, Sava T, De Giorgi U, Cavaliere C, Macrini S, Spizzo G, Aieta M, Messina C, Tucci M, Lodde M, Mansueto G, Zucali PA, Alesini D, D'Angelo A, Massari F, Morelli F, Procopio G, Ratta R, Fratino L, Lo Re G, Pegoraro MC, Zustovich F, Vicario G, Ruatta F, **Federico P**, La Russa F, Burgio SL, Maines F, Veccia A, Galligioni E.
Urol Oncol. 2015 Jun; 33(6):265.e15-21.doi: 10.1016/j.urolonc.2015.02.016.Epub 2015Apr20.

Incomplete Cross-Resistance between taxanes for advanced urothelial carcinoma: implications for clinical practice and trial design.

Sonpavde G, Pond GR, Mullane S, Qu AQ, Di Lorenzo G, **Federico P**, necchi A, Rosenberg JE, Bellmunt J, Choueiri TK.

Clin Genitourin Cancer 2015 Jun; 13(3):250-6.doi:10.1016/j.clgc.2014.10.005.Epub 2014 Nov 7.

Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.

Buonerba C, Pond GR, Sonpavde G, **Federico P**, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G.

Future Oncol. 2013 Jun;9(6):889-97. doi: 10.2217/fon.13.39.

The epidermal growth factor receptors as biological targets in penile cancer.

Di Lorenzo G, Buonerba C, Ferro M, Calderoni G, Bozza G, **Federico P**, Tedesco B, Ruggieri V, Aieta M. Expert Opin Biol Ther 2015 Apr; 15(4):473-6.doi:10.1517/14712598.2015.993377.Epub2014 Dec11..

Non-AIDS-related Kaposi's sarcoma: A single-institution experience.

Rescigno P, Di Trollo R, Buonerba C, De Fata G, **Federico P**, Bosso D, Virtuoso A, Izzo M, Policastro T, Vaccaro L, Cimmino G, Perri F, Matano E, Delfino M, De Placido S, Palmieri G, Di Lorenzo G.

World J Clin Oncol. 2013 May 10;4(2):52-7. doi: 10.5306/wjco.v4.i2.52.

Calcitriol: a better option than vitamin D in denosumab-treated patients with kidney failure?

Buonerba C, Caraglia M, Malgieri S, Perri F, Bosso D, **Federico P**, Ferro M, Rizzo M, Palmieri G, Di Lorenzo G.

Expert Opin Biol Ther. 2013 Feb;13(2):149-51. doi: 10.1517/14712598.2012.756470. Epub 2012 Dec 25.

Peg-filgrastim and cabazitaxel in prostate cancer patients.

Di Lorenzo G, D'Aniello C, Buonerba C, **Federico P**, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S.

Anticancer Drugs. 2013 Jan;24(1):84-9. doi: 10.1097/CAD.0b013e32835a56bc.

Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis.
Di Lorenzo G, Buonerba C, **Federico P**, Perdonà S, Aieta M, Rescigno P, D'Aniello C, Puglia L, Petremolo A, Ferro M, Marinelli A, Palmieri G, Sonpavde G, Mirone V, De Placido S.
BJU Int. 2012 Dec;110(11 Pt B):E661-6. doi: 10.1111/j.1464-410X.2012.11453.x. Epub 2012 Sep 10.

Non-small cell lung cancer: from targeted therapy to tailored therapy.
Malgieri S, Feliciano S, Bosso D, **Federico P**, Palmieri G, De Placido S, Di Lorenzo G, Buonerba C.
Expert Opin Pharmacother. 2012 Sep;13(13):1817-9.

Everolimus plus long-acting somatostatin analogs in thymic epithelial malignancies.
Palmieri G, Buonerba C, **Federico P**, Formisano L, Nappi L, Di Lorenzo G, Marino M, Damiano V.
World J Clin Oncol. 2012 Jul 10;3(7):111-5. doi: 10.5306/wjco.v3.i7.111.

Combination of docetaxel and cetuximab for penile cancer: a case report and literature review.
Rescigno P, Matano E, Raimondo L, Mainolfi C, **Federico P**, Buonerba C, Di Trollo R, D'Aniello C, Damiano V, Palmieri G, De Placido S, Di Lorenzo G.
Anticancer Drugs. 2012 Jun;23(5):573-7. doi: 10.1097/CAD.0b013e328350ead7.

Imatinib mesylate in thymic epithelial malignancies.
Palmieri G, Marino M, Buonerba C, **Federico P**, Conti S, Milella M, Petillo L, Evoli A, Lalle M, Ceribelli A, Merola G, Matano E, Sioletic S, De Placido S, Di Lorenzo G, Damiano V.
Cancer Chemother Pharmacol. 2012 Feb;69(2):309-15. doi: 10.1007/s00280-011-1690-0. Epub 2012 Jun 28.

Combined imaging with 18F-FDG-PET/CT and 111In-labeled octreotide SPECT for evaluation of thymic epithelial tumors.
De Luca S, Fonti R, Palmieri G, **Federico P**, Del Prete G, Pacelli R, Pace L, De Placido S, Salvatore M, Del Vecchio S.
Clin Nucl Med. 2013 May;38(5):354-8.

Foreign Languages: English


Participation in therapeutic trials and in the principles of GCP during last three years: 2010-2014:: Phase I, II, III (Oncology: genitourinary area) as sub-investigator

Last GCP training: Jan 2014

I hereby authorize the treatment of the personal data in compliance with the Italian Law (LD 196/2003)

Date: 7 Jan 2016

Signature:

A handwritten signature in black ink that reads "Piera Federico". The signature is written in a cursive style and is placed on a light-colored rectangular background.

